GYNECOLOGY

Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2)

May 13, 2017 by in GYNECOLOGY Comments Off on Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2)

Objective To evaluate PIK3CA mutational status and c-erbB2 gene amplification in a series of primary uterine serous carcinomas (USC) cell lines. To assess the efficacy of GDC-0980, a potent inhibitor…

read more

Risk-adjusted models for adverse obstetric outcomes and variation in risk-adjusted outcomes across hospitals

May 13, 2017 by in GYNECOLOGY Comments Off on Risk-adjusted models for adverse obstetric outcomes and variation in risk-adjusted outcomes across hospitals

Objective Regulatory bodies and insurers evaluate hospital quality using obstetrical outcomes, however meaningful comparisons should take preexisting patient characteristics into account. Furthermore, if risk-adjusted outcomes are consistent within a hospital, fewer…

read more

Markedly different rates of incident insulin treatment based on universal gestational diabetes mellitus screening in a diverse HMO population

May 13, 2017 by in GYNECOLOGY Comments Off on Markedly different rates of incident insulin treatment based on universal gestational diabetes mellitus screening in a diverse HMO population

Objective We sought to evaluate population gestational diabetes mellitus (GDM) screening results and risk for incident insulin treatment. Study Design Among 64,687 pregnant women universally screened for GDM from 1995…

read more
Get Clinical Tree app for offline access